Sign in

James E. Davis

Chairman, CEO, and President at QUEST DIAGNOSTICS
Board
Since November 1, 2022
Age
62 years
Tenure
Joined DGX in April 2013 as Senior Vice President and advanced through roles including Executive Vice President, CEO‐Elect on February 3, 2022, Chief Executive Officer and President on November 1, 2022, and ultimately as Chairman on April 1, 2023.

Also at QUEST DIAGNOSTICS

CTD
Catherine T. Doherty
Senior Vice President, Regional Businesses
KK
Karthik Kuppusamy
Senior Vice President, Clinical Solutions
MAG
Mark A. Gardner
Senior Vice President, Molecular Genomics and Oncology

About

At 62 years old as of fiscal year 2024, the executive has dedicated his career to advancing healthcare and diagnostics, consistently delivering strategic leadership in complex, global organizations.

His professional journey at DGX began when he joined Quest Diagnostics on April 1, 2013 as Senior Vice President, Diagnostics Solutions, where he played a pivotal role in redefining diagnostic information services. Over time, he earned successive promotions, including a key role as Executive Vice President, followed by his appointment as CEO‐Elect on February 3, 2022 and then as Chief Executive Officer and President on November 1, 2022.

Prior to his tenure at DGX, he demonstrated his executive acumen by serving as CEO at InSightec, Inc. and holding various senior positions at General Electric’s healthcare business, among other leadership roles. His career reflects a steadfast commitment to operational excellence, innovation, and transforming business strategies in the healthcare industry.

$DGX Performance Under James E. Davis

Past Roles

OrganizationRoleDate RangeDetails
Quest Diagnostics (DGX) CEO-ElectFeb 3, 2022 - Nov 1, 2022Predecessor role; ended upon promotion to Chairman, CEO, and President
Quest Diagnostics (DGX) Executive Vice President, General DiagnosticsJan 2017 - (ended upon promotion)Managed a portfolio of businesses and refocused the company on diagnostic information services
Quest Diagnostics (DGX) Senior Vice President, Diagnostics SolutionsApril 2013 - (subsequent transition)Focused on healthcare IT, risk assessment, clinical trials, diagnostic products, and employer solutions
Quest Diagnostics (DGX) Products Business ManagerFeb 2014 - 2016Oversaw the products business
Quest Diagnostics (DGX) General Management, Regional Diagnostic Information ServicesJanuary 2015 - (unclear end date)Assumed responsibility for the regional Diagnostic Information Services business
InSightec, Inc. Lead Director and later Chief Executive OfficerMar 2012 - Apr 2013Led development of ultrasound ablation devices guided by MRI systems
General Electric (GE) VP & GM, GE Healthcare’s MRI Business; also held leadership roles in aviation2007 - 2012Managed GE Healthcare's magnetic resonance imaging business and led strategic operational improvements in aviation
McKinsey & Company, Inc. ConsultantN/ADeveloped strategic and operational improvement initiatives

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Base Salary (Actual Paid)$1,175,000 Paid throughout 2023 (adjusted timing)Fixed annual base salary
Matching Contributions (401(k))$16,500 2023 per plan guidelinesMatching contributions under the 401(k) Plan
Matching Credits (SDCP)$72,306 2023 per plan provisionsMatching credits under the Supplemental Deferred Compensation Plan (SDCP)

Performance Compensation

Data from  FY 2023

Performance Shares

MetricValue/ConditionDetails
Weight for Revenue CAGR50% Includes COVID-19 revenues during performance period
Weight for Average ROIC30% Specific targets undisclosed
Weight for Relative TSR20% Payouts vary: ≥75th: 2x; 50th: 1x; 25th: 0.5x; <25th: 0x
Threshold Award2,517 shares Minimum performance level
Target Award33,562 shares Performance target
Maximum Award67,124 shares Cap on award
Vesting ScheduleVests after 3-year period ending Dec 31, 2025 Evaluation Period: Jan 1, 2023 – Dec 31, 2025
Grant DateFeb 23, 2023
Grant Date Fair Value$4,790,640
Grant Date Stock Price$142.44

Non-Equity Incentive Plan (SMIP)

MetricValueDetails
Threshold Payout$440,625 Minimum performance level
Target Payout$1,762,500 Established target
Maximum Payout$3,525,000 Cap on incentive payout
Actual Payment$1,361,531 115.9% of target; 77.25% of salary
Adjusted Diluted EPS$8.71 Factored into performance evaluation
Payment BasisCash-basedAward paid annually; no vesting schedule
Grant DateFeb 23, 2023

Accelerated Vesting of Performance Shares

MetricValue/ConditionDetails
Accelerated Vesting Value$16,887,478 If termination occurs on Dec 31, 2023
Vesting ConditionIf terminated on Dec 31, 2023Based on the greater of actual versus target performance